TY - JOUR
T1 - Tumor-Reactive cd8+ tcells in metastatic gastrointestinal cancer refractory to chemotherapy
AU - Turcotte, Simon
AU - Gros, Alena
AU - Tran, Eric
AU - Lee, Chyi Chia R.
AU - Wunderlich, John R.
AU - Robbins, Paul F.
AU - Rosenberg, Steven A.
PY - 2014/1/15
Y1 - 2014/1/15
N2 - Purpose: To evaluate whether patients with metastatic gastrointestinal adenocarcinomas refractory to chemotherapy harbor tumor-reactive cytotoxic T cells. Experimental Design: Expansion ofCD8 + tumor-infiltrating lymphocytes (TIL) and cancer cell lines was attempted from gastrointestinal cancer metastases in 16 consecutive patients for the study of antitumor immune recognition. Retroviral transduction of genes encoding T-cell receptors (TCR) was used to define HLA-restriction elements and specific reactivity. Results: TIL were expanded from metastases in all patients, and new tumor cell lines were generated in 5 patients. Autologous tumor recognition without cross-reactivity against allogeneic HLA-matched gastrointestinal tumors was found in CD8 + TIL from 3 of these 5 patients. In a patient with gastric cancer liver metastases, the repertoire of CD8 + TIL was dominated by cytolytic sister clones reactive to 2 out of 4 autologous cancer cell lines restricted by HLA-C*0701. From the same patient, a rare CD8 + TIL clone with a distinct TCR recognized all four cancer cell lines restricted by HLA-B*4901. In a patient with bile duct cancer, two distinct antitumor cytolytic clones were isolated from a highly polyclonal CD8 + TIL repertoire. TCRs isolated from these clones recognized epitopes restricted by HLA-A*201. In a third patient, CD8 + TIL reactivity was progressively lost against an autologous colon cancer cell line that displayed loss of HLA haplotype. Conclusions: This study provides a basis for the development of immunotherapy for patients with advanced gastrointestinal malignancies by first establishing the presence of naturally occurring tumorreactive CD8 + TIL at the molecular level. Clin Cancer Res; 20(2); 331-43.
AB - Purpose: To evaluate whether patients with metastatic gastrointestinal adenocarcinomas refractory to chemotherapy harbor tumor-reactive cytotoxic T cells. Experimental Design: Expansion ofCD8 + tumor-infiltrating lymphocytes (TIL) and cancer cell lines was attempted from gastrointestinal cancer metastases in 16 consecutive patients for the study of antitumor immune recognition. Retroviral transduction of genes encoding T-cell receptors (TCR) was used to define HLA-restriction elements and specific reactivity. Results: TIL were expanded from metastases in all patients, and new tumor cell lines were generated in 5 patients. Autologous tumor recognition without cross-reactivity against allogeneic HLA-matched gastrointestinal tumors was found in CD8 + TIL from 3 of these 5 patients. In a patient with gastric cancer liver metastases, the repertoire of CD8 + TIL was dominated by cytolytic sister clones reactive to 2 out of 4 autologous cancer cell lines restricted by HLA-C*0701. From the same patient, a rare CD8 + TIL clone with a distinct TCR recognized all four cancer cell lines restricted by HLA-B*4901. In a patient with bile duct cancer, two distinct antitumor cytolytic clones were isolated from a highly polyclonal CD8 + TIL repertoire. TCRs isolated from these clones recognized epitopes restricted by HLA-A*201. In a third patient, CD8 + TIL reactivity was progressively lost against an autologous colon cancer cell line that displayed loss of HLA haplotype. Conclusions: This study provides a basis for the development of immunotherapy for patients with advanced gastrointestinal malignancies by first establishing the presence of naturally occurring tumorreactive CD8 + TIL at the molecular level. Clin Cancer Res; 20(2); 331-43.
UR - http://www.scopus.com/inward/record.url?scp=84892711807&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84892711807&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-13-1736
DO - 10.1158/1078-0432.CCR-13-1736
M3 - Article
C2 - 24218514
AN - SCOPUS:84892711807
SN - 1078-0432
VL - 20
SP - 331
EP - 343
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 2
ER -